6 recruiting, 4 active not recruiting, 1 terminated, 1 withdrawn. 7 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 4, Active not recruiting 2, Terminated 1 |
| Phase 2 | 6 | Active not recruiting 3, Recruiting 2, Withdrawn 1 |
Follow Refractory Transformed Chronic Lymphocytic Leukemia: new trials by email Literature Review of Refractory Transformed Chronic Lymphocytic Leukemia trials Research Report on Refractory Transformed Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 23 | 2025-08-14 | 2026-09-16 |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia | Phase 2 | Withdrawn | Northwestern University | 2024-03-29 | 2024-02-29 | |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 36 | 2024-01-02 | 2026-10-08 |
| Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia | Phase 2 | Recruiting | Aseel Alsouqi | 24 | 2023-07-28 | 2026-03-03 |
| Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | City of Hope Medical Center | 9 | 2023-06-02 | 2026-10-01 |
| CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563, Bendamustine, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 25 | 2022-10-03 | 2026-06-09 |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
| Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome Atezolizumab, Laboratory Biomarker Analysis, Obinutuzumab - Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 50 | 2017-01-31 | 2026-08-10 |
Leukemia, Lymphocytic, Chronic, B-Cell (7) · Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, B-Cell (3) · Lymphoma, Follicular (3) · Lymphoma, Mantle-Cell (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, B-Cell, Marginal Zone (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Blast Crisis (1) · Burkitt Lymphoma (1) · Leukemia, Lymphoid (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Prolymphocytic, B-Cell (1)
Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphatic Diseases (8) · Lymphoproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Chronic Disease (7) · Disease Attributes (7) · Hematologic Diseases (7) · Leukemia (7) · Leukemia, B-Cell (7) · Lymphoma (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7)
Biopsy (10) · Specimen Handling (10) · Magnetic Resonance Spectroscopy (9) · Cyclophosphamide (8) · Leukapheresis (5) · fludarabine (5) · Blood Component Removal (3) · fludarabine phosphate (3) · Bendamustine Hydrochloride (2) · Nivolumab (2) · venetoclax (2) · zanubrutinib (2) · CT-P10 (1) · High-Energy Shock Waves (1) · Immunotherapy, Adoptive (1)
City of Hope Medical Center (3) · Mayo Clinic (2) · Aseel Alsouqi (1) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · Northwestern University (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · Sumithira Vasu (1)
United States (12)
Sumithira Vasu, MD (2) · Alexey V Danilov (1) · Francisco J Hernandez-ILizaliturri (1) · Jennifer A Woyach, MD (1) · Mazyar Shadman (1) · Mohamed A. Kharfan-Dabaja, M.D., M.B.A. (1) · Nitin Jain (1) · Saad J. Kenderian, M.D. (1) · Shuo Ma, MD, PhD (1) · Swetha Kambhampati (1) · Tanya Siddiqi (1)
P30CA033572 (3), P30CA060553 (1), R01CA276374 (1)